AU2014354797C1 - MERS-CoV vaccine - Google Patents

MERS-CoV vaccine Download PDF

Info

Publication number
AU2014354797C1
AU2014354797C1 AU2014354797A AU2014354797A AU2014354797C1 AU 2014354797 C1 AU2014354797 C1 AU 2014354797C1 AU 2014354797 A AU2014354797 A AU 2014354797A AU 2014354797 A AU2014354797 A AU 2014354797A AU 2014354797 C1 AU2014354797 C1 AU 2014354797C1
Authority
AU
Australia
Prior art keywords
ser
leu
val
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014354797A
Other languages
English (en)
Other versions
AU2014354797B2 (en
AU2014354797A1 (en
Inventor
Karuppiah Muthumani
Niranjan Y. Sardesai
David B. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania
Publication of AU2014354797A1 publication Critical patent/AU2014354797A1/en
Publication of AU2014354797B2 publication Critical patent/AU2014354797B2/en
Application granted granted Critical
Publication of AU2014354797C1 publication Critical patent/AU2014354797C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014354797A 2013-11-29 2014-11-26 MERS-CoV vaccine Ceased AU2014354797C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29
US61/910,153 2013-11-29
PCT/US2014/067537 WO2015081155A1 (en) 2013-11-29 2014-11-26 Mers-cov vaccine

Publications (3)

Publication Number Publication Date
AU2014354797A1 AU2014354797A1 (en) 2016-07-07
AU2014354797B2 AU2014354797B2 (en) 2017-10-26
AU2014354797C1 true AU2014354797C1 (en) 2018-02-01

Family

ID=53199622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014354797A Ceased AU2014354797C1 (en) 2013-11-29 2014-11-26 MERS-CoV vaccine

Country Status (10)

Country Link
US (5) US10016497B2 (enExample)
EP (1) EP3074051A4 (enExample)
JP (1) JP6412131B2 (enExample)
KR (2) KR20160091350A (enExample)
CN (2) CN112057613A (enExample)
AU (1) AU2014354797C1 (enExample)
CA (1) CA2932055A1 (enExample)
IL (3) IL305392A (enExample)
SA (1) SA516371223B1 (enExample)
WO (1) WO2015081155A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134439A1 (en) 2013-03-01 2014-09-04 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
US11058779B2 (en) 2015-09-08 2021-07-13 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
KR102017217B1 (ko) * 2017-10-19 2019-09-02 주식회사 엔케이맥스 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
JP2023511780A (ja) 2020-02-25 2023-03-22 イノビオ ファーマシューティカルズ，インコーポレイティド コロナウイルスに対するワクチンおよび使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
US20230181681A1 (en) * 2020-05-08 2023-06-15 Industry Academic Cooperation Foundation, Hallym University Peptide for suppressing coronavirus and use thereof
US20230226170A1 (en) * 2020-05-12 2023-07-20 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
WO2021252604A1 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
WO2022011332A2 (en) * 2020-07-10 2022-01-13 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
WO2022020604A1 (en) * 2020-07-22 2022-01-27 Greffex, Inc. Multivalent beta-coronavirus vaccines, their design and uses
US20230279361A1 (en) * 2020-07-27 2023-09-07 National University Corporation Shiga University Of Medical Science Method for in vitro proliferating virus belonging to family coronaviridae, method for producing neutralizing antibody to virus belonging to family coronaviridae, and method for producing infection model of severe acute respiratory syndrome coronavirus 2
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
US20240016919A1 (en) * 2020-08-25 2024-01-18 The Wistar Institute Of Anatomy And Biology INTRADERMAL MERS-CoV VACCINE
US20230349889A1 (en) * 2020-09-10 2023-11-02 The Council Of The Queensland Institute Of Medical Research Methods of Determining Immune Response
AU2021340715A1 (en) * 2020-09-11 2023-04-27 Mark J. Cantwell Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
EP1183068A4 (en) 1999-05-10 2008-12-17 Gentronics Inc ENHANCED ACTIVE AGENT DELIVERY METHOD BY ELECTROPORATION
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US7803918B2 (en) * 2003-08-18 2010-09-28 Amsterdam Institute Of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
AU2005250477A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN103476928B (zh) * 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
EP2788478B1 (en) * 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
EP3046579A1 (en) 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
KR20160091350A (ko) * 2013-11-29 2016-08-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SONG F, et al., 'Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies,' Journal of Virology, (2013) vol 87 No 21, pp 11950-11954 *

Also Published As

Publication number Publication date
WO2015081155A1 (en) 2015-06-04
CA2932055A1 (en) 2015-06-04
AU2014354797B2 (en) 2017-10-26
US20200222527A1 (en) 2020-07-16
AU2014354797A1 (en) 2016-07-07
CN105939730A (zh) 2016-09-14
SA516371223B1 (ar) 2023-01-31
IL245903A0 (en) 2016-07-31
JP2016539946A (ja) 2016-12-22
US20210401972A1 (en) 2021-12-30
IL305392A (en) 2023-10-01
CN112057613A (zh) 2020-12-11
CN105939730B (zh) 2020-09-11
US20190022213A1 (en) 2019-01-24
US11135284B2 (en) 2021-10-05
US10016497B2 (en) 2018-07-10
EP3074051A4 (en) 2017-04-12
US20170258893A1 (en) 2017-09-14
US20240123056A1 (en) 2024-04-18
KR20160091350A (ko) 2016-08-02
IL276210A (en) 2020-09-30
IL276210B2 (en) 2024-01-01
KR20230122181A (ko) 2023-08-22
IL276210B1 (en) 2023-09-01
JP6412131B2 (ja) 2018-10-24
IL245903B (en) 2020-08-31
US11801298B2 (en) 2023-10-31
EP3074051A1 (en) 2016-10-05
US10548971B2 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
US11801298B2 (en) MERS-CoV vaccine
KR102011026B1 (ko) 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
AU2017329044B2 (en) Combination of novel vaccines against Zika virus and DNA antibody constructs for use against Zika virus
JP6293485B2 (ja) コンセンサス抗原コンストラクトおよびそれらから作製されるワクチン、ならびにそれらを使用するマラリアの治療方法
US20210283242A1 (en) Immune-mediated coronavirus treatments
AU2019204991A1 (en) Vaccines with biomolecular adjuvants
JP7765407B2 (ja) 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法
JP2016538246A (ja) アジュバントとしてのインターロイキン−３３を有するワクチン
KR20170129804A (ko) Cd40 리간드를 어쥬번트로서 갖는 백신
KR102211077B1 (ko) 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
KR20220149907A (ko) 환자의 예방접종 및 치료를 위한 포와산(powassan) 바이러스 항원 및 관련 조성물, 및 그의 용도
HK40042641A (en) Mers-cov vaccine
US20250249088A1 (en) THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-CoV-2
US20230210981A1 (en) Coronavirus disease 2019 (covid-19) combination vaccine
HK1228285A1 (en) Mers-cov vaccine
TW202400635A (zh) 針對sars-cov-2變異體之免疫原性組合物及其使用方法
HK1228285B (en) Mers-cov vaccine
JP2024540322A (ja) ＳＡＲＳ－ＣｏＶ－２によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン
HK1249066A1 (zh) Isg15和其作为佐剂的用途
HK1190329A (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 OCT 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 OCT 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired